Abstract
Angiogenesis and vasculogenesis, regulated by VEGF/VEGFR signaling pathways, play key roles in tumor growth and metastasis. Selective inhibition of VEGFR kinase has been explored as a highly successful clinical strategy in cancer treatment. A number of VEGFR inhibitors have been approved in clinical use and many more are in various stages of drug development. This paper reviews selective small-molecule VEGFR inhibitors in clinical uses and in clinical trials, with particular focus on in vitro, in vivo and clinical trial results of these inhibitors. The VEGF/VEGFR genes and signaling pathways involved in tumor angiogenesis, and the strategies for accessing and improving the therapeutic efficacy of VEGFR inhibitors are also discussed.
Keywords: Selective, VEGFR inhibitor, anticancer, angiogenesis, vasculogenesis, tumor growth, metastasis, clinical trials, signaling pathways, growth factors
Current Pharmaceutical Design
Title:Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Volume: 18 Issue: 20
Author(s): Cunlong Zhang, Chunyan Tan, Huaiwei Ding, Tian Xin and Yuyang Jiang
Affiliation:
Keywords: Selective, VEGFR inhibitor, anticancer, angiogenesis, vasculogenesis, tumor growth, metastasis, clinical trials, signaling pathways, growth factors
Abstract: Angiogenesis and vasculogenesis, regulated by VEGF/VEGFR signaling pathways, play key roles in tumor growth and metastasis. Selective inhibition of VEGFR kinase has been explored as a highly successful clinical strategy in cancer treatment. A number of VEGFR inhibitors have been approved in clinical use and many more are in various stages of drug development. This paper reviews selective small-molecule VEGFR inhibitors in clinical uses and in clinical trials, with particular focus on in vitro, in vivo and clinical trial results of these inhibitors. The VEGF/VEGFR genes and signaling pathways involved in tumor angiogenesis, and the strategies for accessing and improving the therapeutic efficacy of VEGFR inhibitors are also discussed.
Export Options
About this article
Cite this article as:
Zhang Cunlong, Tan Chunyan, Ding Huaiwei, Xin Tian and Jiang Yuyang, Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials, Current Pharmaceutical Design 2012; 18 (20) . https://dx.doi.org/10.2174/138161212800672732
DOI https://dx.doi.org/10.2174/138161212800672732 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Current Cancer Drug Targets Novel Mitotic Targets and Their Small-Molecule Inhibitors
Current Cancer Drug Targets Soy Saponins and the Anticancer Effects of Soybeans and Soy-Based Foods
Current Medicinal Chemistry - Anti-Cancer Agents Synthesis of 9-O-3-(1-piperazinyl/morpholinyl/piperidinyl)pentyl-berberines as Potential Antioxidant and Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry MiR-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer SW480 Cells <i>via</i> Targeting STAT3
Recent Patents on Anti-Cancer Drug Discovery Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Melatonin and Hypothalamic-Pituitary-Gonadal Axis
Current Medicinal Chemistry Impact of Metformin on Male Reproduction
Current Pharmaceutical Design Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting 5-Lipoxygenase for Prevention and Treatment of Cancer
Current Enzyme Inhibition Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry FRET Based Ratio-Metric Sensing of Hyaluronidase in Synthetic Urine as a Biomarker for Bladder and Prostate Cancer
Current Pharmaceutical Biotechnology Potential Clinical Applications of Multi-functional Milk Proteins and Peptides in Cancer Management
Current Medicinal Chemistry The ALK Gene, An Attractive Target for Inhibitor Development
Current Topics in Medicinal Chemistry Radiolabeled Probes Targeting G-Protein-Coupled Receptors for Personalized Medicine
Current Pharmaceutical Design SNPs of Metabolic Syndrome are Associated with Benign Prostatic Hyperplasia Development and Progression in Chinese Population
Current Bioinformatics Metabolism of Flavonoids in Human: A Comprehensive Review
Current Drug Metabolism A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Current Gene Therapy